MOUNTAIN VIEW, California, May 17, 2011 /PRNewswire/ -- AccessClosure, Inc., the market segment leader in extravascular closure devices, announced today an exclusive agreement with Biosensors International for the distribution of the Mynx(TM) Vascular Closure Device throughout the United Kingdom, Switzerland and France. The extravascular Mynx device, designed for patient comfort while providing hemostasis without sutures or implants, will be sold as part of Biosensors' interventional cardiology product range.
"These European countries represent a meaningful market opportunity for us, and we are pleased to be able to partner with Biosensors' established sales force for the distribution of Mynx," said Gregory D. Casciaro, President and CEO of AccessClosure. "Distribution in international markets is a key component of AccessClosure's growth strategy, and provides an excellent complement to our direct sales presence in the United States."
Biosensors will join AccessClosure's existing and growing global network of distributors. Biosensors is now the fifth largest drug-eluting stent (DES) supplier globally, marketing its BioMatrix(TM) family of DES systems which offer the unique combination of Biolimus A9(TM), an anti-restenotic drug developed by Biosensors exclusively for use with DES, and an abluminally-coated biodegradable polymer. Biosensors has a well established direct presence in the UK, Switzerland and France, and will provide AccessClosure with broad and rapid access to those markets.
"We are pleased to offer the Mynx device as part of our interventional cardiology product range" said Jeffrey B. Jump, CEO of Biosensors. "The Mynx device, paired with our portfolio of drug-eluting and bare-metal stents, allows us to offer a more complete solution to our customers. The Mynx has had great success in the United States and other international markets, and we anticipate similar success in these European countries."
The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to immediately seal the femoral artery. Dissolving within 30 days, Mynx leaves nothing behind but a healed artery. The extravascular device is designed for increased patient comfort and clinical versatility. The Mynx, which received its first FDA approval in May 2007, has been used in over 800,000 procedures to date.
About AccessClosure, Inc.
Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience. For more information, please visit our website at http://www.accessclosure.com/
About Biosensors International
Biosensors International develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. With the increasing use of the BioMatrix(TM) family of drug-eluting stent systems, we are rapidly emerging as a leader in the global coronary stent market. For more information, please visit www.biosensors.com .
SOURCE AccessClosure, Inc.